To quantitatively assess the performance and mode of action of GT-02287 and GT-02329, a biochemical protocol was developed, building on methods previously used to evaluate STARs that enhance galactosidase beta 1 (GLB1) activity in GLB1-related LSDs such as GM1 gangliosidosis [16,18,19]. Here, GLB1 is linked to GM1 gangliosidosis.